{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:33:42Z","timestamp":1787002422342,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/cgt.2016.29","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T07:38:45Z","timestamp":1471592325000},"page":"266-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A\/IFN-\u03bb2 or IL-29\/IFN-\u03bb1"],"prefix":"10.1038","volume":"23","author":[{"given":"K","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ohrui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Numasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,19]]},"reference":[{"key":"BFcgt201629_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFN-\u03bbs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69\u201377.","journal-title":"Nat Immunol"},{"key":"BFcgt201629_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63\u201368.","journal-title":"Nat Immunol"},{"key":"BFcgt201629_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164\u2013171.","journal-title":"Nat Genet"},{"key":"BFcgt201629_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR . Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8\u201332.","journal-title":"Immunol Rev"},{"key":"BFcgt201629_CR5","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1128\/JVI.02438-06","volume":"81","author":"Z Zhou","year":"2007","unstructured":"Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R . Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749\u20137758.","journal-title":"J Virol"},{"key":"BFcgt201629_CR6","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/j.1349-7006.2011.02079.x","volume":"102","author":"H Fujie","year":"2011","unstructured":"Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T et al. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011; 102: 1977\u20131990.","journal-title":"Cancer Sci"},{"key":"BFcgt201629_CR7","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.4049\/jimmunol.178.8.5086","volume":"178","author":"M Numasaki","year":"2007","unstructured":"Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178: 5086\u20135098.","journal-title":"J Immunol"},{"key":"BFcgt201629_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejca.2009.10.002","volume":"46","author":"Q Li","year":"2010","unstructured":"Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer 2010; 46: 180\u2013190.","journal-title":"Eur J Cancer"},{"key":"BFcgt201629_CR9","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/bjc.2011.379","volume":"105","author":"Q Li","year":"2011","unstructured":"Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M et al. Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-\u03bb genes produced anti-tumour effects. Br J Cancer 2011; 105: 1302\u20131312.","journal-title":"Br J Cancer"},{"key":"BFcgt201629_CR10","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","volume":"176","author":"A Sato","year":"2006","unstructured":"Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T . Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006; 176: 7686\u20137694.","journal-title":"J Immunol"},{"key":"BFcgt201629_CR11","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-05-3653","volume":"66","author":"A Lasfar","year":"2006","unstructured":"Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468\u20134477.","journal-title":"Cancer Res"},{"key":"BFcgt201629_CR12","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00262-010-0831-3","volume":"59","author":"W Abushahba","year":"2010","unstructured":"Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010; 59: 1059\u20131071.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcgt201629_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.lungcan.2012.09.005","volume":"78","author":"Y Tezuka","year":"2012","unstructured":"Tezuka Y, Endo S, Matsui A, Sato A, Saito K, Semba K et al. Potential anti-tumor effect of IFN-\u03bb2 (IL-28A) against human lung cancer cells. Lung Cancer 2012; 78: 185\u2013192.","journal-title":"Lung Cancer"},{"key":"BFcgt201629_CR14","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2002-05-1461","volume":"101","author":"M Numasaki","year":"2003","unstructured":"Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620\u20132627.","journal-title":"Blood"},{"key":"BFcgt201629_CR15","doi-asserted-by":"publisher","first-page":"32269","DOI":"10.1074\/jbc.M404789200","volume":"279","author":"L Dumoutier","year":"2004","unstructured":"Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC . Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-\u03bb1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269\u201332274.","journal-title":"J Biol Chem"},{"key":"BFcgt201629_CR16","first-page":"4696","volume":"62","author":"JG Segal","year":"2002","unstructured":"Segal JG, Lee NC, Tsung YL, Norton JA, Tsung K . The role of IFN-\u03b3 in rejection of established tumors by IL-12: source of production and target. Cancer Res 2002; 62: 4696\u20134703.","journal-title":"Cancer Res"},{"key":"BFcgt201629_CR17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.V83.5.1289.1289","volume":"83","author":"FM Rosenthal","year":"1994","unstructured":"Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B . Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-\u03b3 cDNAs. Blood 1994; 83: 1289\u20131298.","journal-title":"Blood"},{"key":"BFcgt201629_CR18","first-page":"G960","volume":"289","author":"S Brand","year":"2005","unstructured":"Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol 2005; 289: G960\u2013G968.","journal-title":"Am J Physiol"},{"key":"BFcgt201629_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cyto.2005.04.003","volume":"31","author":"A Meager","year":"2005","unstructured":"Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M . Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109\u2013118.","journal-title":"Cytokine"},{"key":"BFcgt201629_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1089\/cbr.2012.1247","volume":"28","author":"Y Yan","year":"2013","unstructured":"Yan Y, Zhang J, Liu Y, Zhu T, Yuan L, Ge Y et al. Inhibition of lung adenocarcinoma transfected with interleukin 28A recombinant adenovirus (Ad-mIFN-\u03bb2) in vivo. Cancer Biother Radiopharm 2013; 28: 124\u2013130.","journal-title":"Cancer Biother Radiopharm"},{"key":"BFcgt201629_CR21","doi-asserted-by":"publisher","first-page":"E2376","DOI":"10.1073\/pnas.1424241112","volume":"112","author":"F Souza-Fonseca-Guimaraes","year":"2015","unstructured":"Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K et al. NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci USA 2015; 112: E2376\u2013E2384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201629_CR22","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","volume":"188","author":"K Hung","year":"1998","unstructured":"Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H . The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188: 2357\u20132368.","journal-title":"J Exp Med"},{"key":"BFcgt201629_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.168.1.1","volume":"168","author":"BM Segal","year":"2002","unstructured":"Segal BM, Glass DD, Shevach EM . IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002; 168: 1\u20134.","journal-title":"J Immunol"},{"key":"BFcgt201629_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jlb.67.5.607","volume":"67","author":"SR Clarke","year":"2000","unstructured":"Clarke SR . The critical role of CD40\/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J Leukocyte Biol 2000; 67: 607\u2013614.","journal-title":"J Leukocyte Biol"},{"key":"BFcgt201629_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RP Sutmuller","year":"2001","unstructured":"Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823\u2013832.","journal-title":"J Exp Med"},{"key":"BFcgt201629_CR26","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.4049\/jimmunol.176.3.1582","volume":"176","author":"MJ Smyth","year":"2006","unstructured":"Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y . CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176: 1582\u20131587.","journal-title":"J Immunol"},{"key":"BFcgt201629_CR27","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1182\/blood-2005-10-4129","volume":"107","author":"FJ Mennechet","year":"2006","unstructured":"Mennechet FJ, Uz\u00e9 G . Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107: 4417\u20134423.","journal-title":"Blood"},{"key":"BFcgt201629_CR28","first-page":"3399","volume":"61","author":"C Nakajima","year":"2001","unstructured":"Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res 2001; 61: 3399\u20133405.","journal-title":"Cancer Res"},{"key":"BFcgt201629_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.170.3.827","volume":"170","author":"M Kobayashi","year":"1989","unstructured":"Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S et al. Identification and purification of natural killer cell stimulatory factors (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827\u2013845.","journal-title":"J Exp Med"},{"key":"BFcgt201629_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1084\/jem.175.3.779","volume":"175","author":"MJ Robertson","year":"1992","unstructured":"Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D et al. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992; 175: 779\u2013788.","journal-title":"J Exp Med"},{"key":"BFcgt201629_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0008-8749(92)90011-D","volume":"143","author":"MK Gately","year":"1992","unstructured":"Gately MK, Wolitzky AG, Quinn PM, Chizzonite R . Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127\u2013142.","journal-title":"Cell Immunol"},{"key":"BFcgt201629_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1084\/jem.177.4.1199","volume":"177","author":"R Manetti","year":"1993","unstructured":"Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune response and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199\u20131204.","journal-title":"J Exp Med"},{"key":"BFcgt201629_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jss.2003.09.006","volume":"116","author":"JS Hiramoto","year":"2004","unstructured":"Hiramoto JS, Tsung K, Bedolli M, Norton JA, Hirose R . Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12. J Surg Res 2004; 116: 64\u201369.","journal-title":"J Surg Res"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201629.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201629","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201629.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T08:06:42Z","timestamp":1647936402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFcgt201629"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2016.29","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"25 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}